Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of hirsutine in medicine for treating thrombocytopenia

A technology for thrombocytopenia and rhynchophylline, which is applied to the new application of rhynchophylline in the treatment of thrombocytopenia drugs. In the field of preparation of drugs, natural drug compounds can solve the problems of poor treatment effect of thrombocytopenia and achieve Effects of reduced cost of treatment, ease of access, and reduced need for blood transfusion

Pending Publication Date: 2022-03-08
SOUTHWEST MEDICAL UNIVERISTY
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The object of the present invention is to: aim at the problem that the treatment effect of thrombocytopenia in the prior art is not good, provide a kind of application of natural medicine compound rhynchophylline in the preparation of medicine for treating thrombocytopenia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hirsutine in medicine for treating thrombocytopenia
  • Application of hirsutine in medicine for treating thrombocytopenia
  • Application of hirsutine in medicine for treating thrombocytopenia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment ( 1

[0044] Embodiment (one) in vitro experiment

[0045] 1. Main experimental materials

[0046] 1.1 Experimental cells and experimental drugs

[0047] K562 cells: Human erythroleukemia cells, donated by the Central Laboratory of the Affiliated Hospital of Southwest Medical University in May 2017. Meg-01 cells: human megakaryoblastic leukemia cells, purchased from Beijing Zhongyuan Company (ATCC China agent) in March 2019.

[0048] Rhynchophylline, English name Hirsutine, abbreviation HS, CAS: 7729-23-9, molecular weight 368.47. The monomer components were purchased by the research group from Chengdu Pusi Technology Biological Co., Ltd., with a purity of ≥98%, and the production batch number: 19092602. The HS powder should be stored in a dark and dry place at 4°C for a long time. Drugs used for cells: Dimethyl sulfoxide (DMSO) is prepared in an appropriate proportion and stored in a -20°C refrigerator. The storage period does not exceed 3 months.

[0049] 1.2 Main experimen...

Embodiment ( 2

[0085] Embodiment (two) experiment in vivo

[0086] 1. Experimental materials

[0087] 1.1 Experimental animals

[0088] 80 Kunming mice, half male and half female, SPF grade, 4 weeks old, weighing 18-22g, were purchased from Chengdu Dashuo Biotechnology Co., Ltd. (permit number: SCXK (Sichuan) 2013-24), feeding conditions: Southwest Medical Sciences University SPF Animal Center, Sichuan Provincial Experimental Animal Management Committee Experimental Animal Facility Condition Certificate No.: SYXK (Sichuan) 2018-213. Temperature: 25-26°C, Humidity: 45%-70%, 24h light and dark alternate, conventional full-price pellet feed, male and female half and half, reared separately, free to drink water.

[0089] 1.2 Main experimental reagents

[0090] Table 2 Main experimental reagent information

[0091]

[0092] 1.3 Main experimental instruments

[0093] Table 3 Main experimental instrument information

[0094]

[0095] 2 Experimental methods

[0096] 2.1 Experimental m...

Embodiment

[0131] Embodiment (three) molecular mechanism

[0132] 1 Experimental materials

[0133] 1.1 Experimental cells

[0134] K562 cells were selected for the study of related molecular mechanisms. The relevant information is the same as the in vitro section.

[0135] 1.2 Main experimental reagents

[0136] Table 8 Main experimental reagent information

[0137]

[0138]

[0139] 1.3 Main experimental instruments

[0140] Table 9 Main experimental instrument information

[0141]

[0142]

[0143] 2 Experimental methods

[0144] Take K562 cells in the logarithmic growth phase, the cell culture system is 2mL / well, and the number of K562 cells is 2×10 per well 4 cells / mL, the number of Meg-01 cells is 4×10 4 cells / mL were cultured in 6-well plates. The control group (Control) and the HS group (10 μM) were set up respectively, and three replicate wells were set up in each group. All K562 cells were collected at the same time point of drug intervention for 1, 3, 5...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicinal chemistry, in particular to application of hirsutine in preparation of a medicine for treating thrombocytopenia. The hirsutine is shown as a formula I in the specification. According to the application of hirsutine in preparing the medicine, the platelet level in the body can be remarkably improved, the bleeding risk of a patient with thrombocytopenia and the probability that blood needs to be transfused are reduced, and the blood transfusion infection risk is reduced; and compared with the limitation of high treatment cost of TPO and TPO receptor agonists (such as eltrombopag and romiscine), the hirsutine has the advantages of easiness in acquisition, lower cost, small side effect and the like, and can greatly reduce the family burden of patients and reduce the social medical security expenditure pressure.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular to the use of a natural drug compound in the preparation of medicines, in particular to the new use of rhynchophylline in medicines for treating thrombocytopenia. Background technique [0002] Bleeding caused by thrombocytopenia (Thrombocytopenia) is one of the difficult problems in medical treatment today. The etiology of its occurrence mainly involves three categories: decreased platelet production (such as bone marrow failure syndrome), increased platelet clearance (such as immune thrombocytopenic purpura), and prolonged platelet residence time (such as thrombocytopenia caused by hypersplenism, drugs, pregnancy, etc. disease). Among them, the incidence rate of adult primary immune thrombocytopenia (ITP) is about (5-10) / 100,000, and the elderly over 60 years old are the high-incidence group of the disease. Thrombocytopenia caused by ITP is mainly due to humoral or cellular imm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4375A61P7/04
CPCA61K31/4375A61P7/04Y02A50/30
Inventor 吴建明杨靖康雅淇王龙林静吴安国叶云
Owner SOUTHWEST MEDICAL UNIVERISTY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com